Linezolid I.P. 100mg Dry Syrup in PCD pharma franchise in Hyderabad

Linezolid I.P. 100mg Dry Syrup in pharmaceutical manufacturing company in Mumbai

Linezolid I.P. 100mg Dry Syrup in antibiotic pharma franchise in Pune

Linezolid I.P. 100mg Dry Syrup in pharma suppliers in Delhi

Linezolid I.P. 100mg Dry Syrup in pharma export companies in Kolkata
Linezolid I.P. 100mg Dry Syrup in pharma franchise opportunities in Bengaluru

Home/Products /linezolid-100mg-dry-syrup

Linzoglad Dry Syrup

Composition : Linezolid I.P. 100mg Dry Syrup

Dosage Form : Dry Syrup

Packaging Type : with water

Packaging : 30ml

Price : ₹139/-

Linzoglad Dry Syrup is a pediatric formulation containing linezolid, a synthetic antibiotic effective against a range of Gram-positive bacterial infections. It is designed for ease of administration to children, offering a palatable option for those who may have difficulty swallowing tablets. Linezolid works by inhibiting bacterial protein synthesis, making it particularly useful in treating infections caused by resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).

This syrup is indicated for the treatment of various serious infections, including pneumonia, skin and soft tissue infections, and certain types of bacteremia. Its formulation ensures accurate dosing, which is critical in pediatric care. As an oxazolidinone antibiotic, Linzoglad targets the bacterial ribosome, disrupting the production of essential proteins and ultimately leading to bacterial cell death.

Linzoglad is recommended for use under the supervision of a healthcare professional, and its safety profile has been established in clinical trials. Parents and caregivers should closely monitor the child for any adverse reactions and maintain communication with their healthcare provider throughout the treatment course.

Read More

About the Product

Linzoglad Dry Syrup is a pediatric formulation containing linezolid, a synthetic antibiotic effective against a range of Gram-positive bacterial infections. It is designed for ease of administration to children, offering a palatable option for those who may have difficulty swallowing tablets. Linezolid works by inhibiting bacterial protein synthesis, making it particularly useful in treating infections caused by resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).

This syrup is indicated for the treatment of various serious infections, including pneumonia, skin and soft tissue infections, and certain types of bacteremia. Its formulation ensures accurate dosing, which is critical in pediatric care. As an oxazolidinone antibiotic, Linzoglad targets the bacterial ribosome, disrupting the production of essential proteins and ultimately leading to bacterial cell death.

Linzoglad is recommended for use under the supervision of a healthcare professional, and its safety profile has been established in clinical trials. Parents and caregivers should closely monitor the child for any adverse reactions and maintain communication with their healthcare provider throughout the treatment course.

Common side effects may include nausea, diarrhea, headache, and allergic reactions. Serious side effects, such as serotonin syndrome or peripheral neuropathy, should be reported immediately.

Linzoglad Dry Syrup is indicated for the treatment of serious infections caused by susceptible Gram-positive bacteria, including MRSA and VRE.

Use Linzoglad only under medical supervision, and complete the full course of treatment to prevent the development of antibiotic resistance.

Store at room temperature (15-25°C) in a dry place, away from direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation